# Nuclide record paper-tagawa-ac225-j591-jco-2024 (paper). Data CC BY-NC 4.0, attribute "Data from Nuclide (nuclide.cc)". Whole corpus: https://nuclide.cc/api/v1/nuclide.nt
@prefix schema: <https://schema.org/> .
@prefix nuclide: <https://nuclide.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://nuclide.cc/key-papers/paper-tagawa-ac225-j591-jco-2024/>
  a schema:ScholarlyArticle ;
  nuclide:kind "paper" ;
  schema:identifier "paper-tagawa-ac225-j591-jco-2024" ;
  schema:name "Phase I dose-escalation study of 225Ac-J591, a PSMA-targeting alpha-emitting antibody, in mCRPC"@en ;
  schema:description "The first human test of an alpha-emitting radioactive drug attached to an antibody (rather than a small molecule) against PSMA found a safe dose in men with advanced prostate cancer who had exhausted other treatments, and shrank the PSA marker in nearly half of them - including those whose cancer had already stopped responding to the more common lutetium-177 PSMA treatment."@en ;
  schema:url <https://nuclide.cc/key-papers/paper-tagawa-ac225-j591-jco-2024/> ;
  schema:dateModified "2026-09-22"^^xsd:date ;
  schema:citation <https://pubmed.ncbi.nlm.nih.gov/37922438/>, <https://ascopubs.org/doi/10.1200/JCO.23.00573> ;
  nuclide:tag "alpha therapy", "prostate cancer", "phase 1" ;
  schema:sameAs <https://doi.org/10.1200/JCO.23.00573> ;
  schema:datePublished "2024"^^xsd:gYear ;
  schema:author "Tagawa ST, Thomas C, Sartor AO, Sun M, Stangl-Kremser J, et al." ;
  nuclide:related <https://nuclide.cc/drugs/ac225-psma/>, <https://nuclide.cc/technologies/targeted-alpha-therapy/>, <https://nuclide.cc/targets/psma/>, <https://nuclide.cc/indications/prostate-mcrpc/>, <https://nuclide.cc/people/oliver-sartor/>, <https://nuclide.cc/pairings/beta-then-alpha/>, <https://nuclide.cc/isotopes/lu-177/>, <https://nuclide.cc/isotopes/ac-225/> .